Amar Kishan
@AmarUKishan
Followers
3,585
Following
792
Media
35
Statuses
2,858
Radiation Oncologist, Professor, and Executive Vice Chair of Radiation Oncology at UCLA. All views are my own.
Joined November 2017
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
YouTube,YouTube
• 3124028 Tweets
イスラエル
• 201122 Tweets
#เทควันโด
• 129330 Tweets
ゲリラ豪雨
• 76330 Tweets
#ปาฏิหาริย์รักร้อยปีEP9
• 71318 Tweets
高校野球
• 66984 Tweets
CENTURY OF LOVE EP9
• 59401 Tweets
カミナリ
• 49524 Tweets
#8YearsWithBLACKPINK
• 47518 Tweets
ETERNITY WITH BLACKPINK
• 46375 Tweets
#推しの子
• 41354 Tweets
GIVE VINESH SILVER
• 36894 Tweets
帰宅難民
• 31203 Tweets
#띵동띵동_승철이_생일이다_문열어
• 29826 Tweets
Zubimendi
• 29556 Tweets
岐阜城北
• 25862 Tweets
長崎市長
• 23817 Tweets
土砂降り
• 23152 Tweets
セーター
• 15302 Tweets
大橋くん
• 13580 Tweets
San Cayetano
• 13531 Tweets
智弁学園
• 11297 Tweets
JJAM MV OUT NOW
• 10812 Tweets
Pinned Tweet
It’s a pleasure to announce the appointment of Dr.
@AmarUKishan
to Executive Vice Chair for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center.
15
10
129
13
1
82
Proud to share that I have been promoted to Professor! An achievement made possible only by working with exceptional colleagues, residents, and students at an exceptional place!
@MSteinbergMD
@UCLAJCCC
@Ucla
69
9
312
Pleased to share the primary endpoint results of the randomized phase III MIRAGE trial evaluating whether aggressive margin reduction with MRI-guidance leads to reduced toxicity in the context of prostate SBRT, out today in
@JAMAOncology
(1/n)
21
110
253
Pleased to share the results of our "MASTER" systematic review and meta-analysis of local salvage therapies for radioreccurent PCa
@EUPlatinum
8
48
174
Detailed topographic analysis of PSMA-defined recurrences after RP in 226 men suggests a majority of recurrences occur inferiorly and posteriorly. Potentially major implications for post-operative RT contouring.
Detailed PSMA PET mapping of prostatic bed recurrence patterns provides important information for a redefinition of radiotherapy contouring guidelines.
#NuclearMedicine
#ProstateCancer
@AmarUKishan
@a_dalpra
@CalaisJeremie
@MinsongUC
@Matthias_R_Benz
1
43
105
10
30
115
Very pleased to present the 4th MARCAP analysis, "SANDSTORM" now live online at
@JCO_ASCO
(1/n)
7
40
115
Very proud to receive this award from
@dgsomucla
! Kind thanks to my patients, medical students, residents, and colleagues at
@UCLAJCCC
Proud to share that our
#uclaradonc
Dr.
@AmarUKishan
is the 2021 recipient of the prestigious Leonard Tow Humanism in Medicine Award. The award recognizes faculty members who demonstrate clinical excellence & outstanding compassion in the delivery of care.
4
2
54
15
3
105
Very pleased to announce that the LUNAR trial is now open
@UCLAJCCC
. SBRT alone vs. 177Lu-PSMA x 2 + SBRT for oligorecurrent hormone-sensitive prostate cancer!
4
28
104
Happy to share the latest work from the MARCAP consortium, led by outstanding PGY-5
@UCLAJCCC
resident
@MartinMaMDPhD
-- the LEVIATHAN analysis in
@EUplatinum
2
30
97
@PottersMD
I’m disappointed to see this. My disclosures are very upfront. Regardless, this seems to be an attack on my ethics. I ran a randomized trial, which was not funded by industry, and simply am reporting the results. Do my disclosed conflicts of interest impact the findings?
7
1
98
@MartinMaMDPhD
@UCLAJCCC
Early results of our phase II trial of SBRT to the prostate fossa (+/- PLN) SCIMITAR out now in the Red Journal
@ASTRO_org
Quality-of-Life Outcomes and Toxicity Profile Among Patients with Localized Prostate Cancer After Radical Prostatec…
1
14
38
5
22
87
Thank you! Special shoutout to early career support from
@UCLAJCCC
@ASTRO_org
@PCFnews
. Looking forward to optimizing radiation for prostate cancer with
@CDMRP
!
Proud to share that
#uclaradonc
Dr.
@AmarUKishan
has received a $1.1 million grant from the Dept. of Defense to help improve radiation treatment of prostate cancer. Join me in congratulating Dr. Kishan on this win.
@UCLAHealth
@UCLAJCCC
@dgsomucla
19
11
206
7
3
84
Happy to share our new work out in
@JAMAOnc
representing a multi-institutional and cross-trialist group collaborative. I’ll try my hand at a “tweetorial” (1/n)
2
30
74
Large retrospective study highlighting the importance of multimodality therapy in the context of high-risk prostate cancer with aggressive disease features (1/x)
7
21
69
Very proud to have worked on this with a great co-conspirator and MARCAP co-founder
@DrSpratticus
. Years in the making indeed. Thanks to incredible stats by Yilun Sun, to all co-authors, and to
@NRGonc
@EORTC
@TROGfightcancer
@cancertrials_ie
PCS for sharing data. More to come!
Years in the making...
#MARCAP
now online
@TheLancetOncol
. 1st IPD meta-analysis of every eligible RCT evaluating tx intensification with ADT with RT in localized PCa.
Enormous thanks to
@AmarUKishan
and the lead biostatistician Dr. Yilun Sun from
@CWRUSOM
, dozens more.
@RadoncUh
13
70
217
2
9
62
Pleased to link to this new report from the outstanding
@RlePhilipson
and Tahmineh Romero examining the natural history of radiorecurrent high-risk prostate cancer
@Euplatnium
2
15
61
Great work from
@MartinMaMDPhD
(he is on a roll) with a dosimetric post-hoc analysis of a subset of MRgRT patients on our MIRAGE RCT of MR-guided SBRT vs. CT-guided SBRT. (1/n)
6
18
57
Happy to share excellent work from
@UCLAJCCC
PGY-5 Ritchell van Dams evaluating efficacy and safety of SBRT for high-risk PCa in an international consortium . Thanks to great collaborators including
@VedangMurthy
@SbrtSean
@DrAndrewLoblaw
@MSteinbergMD
2
10
59
Pleased to report the publication of the 5th MARCAP analysis, BCRSCRAP, in
@JCO_ASCO
today! Led by
@SouMyajiT_RO
and Tahmineh Romero
@UCLAJCCC
2
23
59
A very thoughtful and creative gift from
@MartinMaMDPhD
commemorating our many shared projects (of course, all with good acronyms if I may say so).
@UCLAJCCC
@UCLAradonc
6
0
57
Great work led by
@bethneilsen
out in
@IJROBP
looking at the dosimetric impact of trigone/bladder displacements and toxicity in the MIRAGE trial
2
12
55
Excellent work by
@MartinMaMDPhD
and
@SouMyajiT_RO
in press on the definition of BCR in the era of SBRT
4
15
52
Great work by
@Rlevinepstein
comparing three "ablative" monotherapy options for PCa: LDR, HDR, and SBRT. No differences in BCRFS.
@SbrtSean
@DrSpratticus
@NicholasZaorsky
@EricLehrer
@BrandonMahal
2
20
50
Happy to share a collaborative study out today in
@JAMANetworkOpen
on favorable long-term outcomes (median f/u 7 years) for SBRT.
@DrAndrewLoblaw
@MSteinbergMD
@DrSpratticus
. Thanks
@UCLAJCCC
for the support!
A
#UCLA
study shows that men with low- or intermediate-risk
#prostatecancer
can safely and effectively be treated with higher doses of radiation over a shorter period of time, reducing treatment from 45 days to four to five days. cc:
@amarukishan
1
4
13
1
19
46
@olusolaodavies
@alison_tree
@drthomaskole
@SbrtSean
@JoanneWeidhaas
I will note I am in the unique position of having 50% folks say the margin is too tight, and the other 50% of folks say the margin could be that tight on any machine. The right answer, of course, is enzalutamide.
2
6
48
So great to hear about the renaissance of SBRT/SABR for RCC from the one and only
@_ShankarSiva
! Looking forward to hearing about FASTRACK II
@ASTRO_org
Lucky enough to meet the wonderful
#radonc
residents of
@UCLAHealth
as Visiting Professor. I also found the world famous UCLA Halloween decoration 🎃👻
Home of ex-Chair Rodney Withers
@PeterMacRadOnc
. Thank you
@AmarUKishan
@MSteinbergMD
for the invitation! Next stop
#ASTRO23
1
6
76
1
7
49
Nice work out in
@IJROBP
led by
@UCLAJCCC
resident
@claysmithmd
. Detailed patterns of failure analysis in 128 patients with PSMA done for radiorecurrent disease, revealing intraprostatic-only failures in ~1/3.
2
21
57
Pleased to share the second report from the MARCAP Consortium, the HEAT Meta-Analysis
New In Press: High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium
@AmarUKishan
@DrSpratticus
et al.
0
11
28
2
13
47
(1/2) Happy to share the paper in press at
@EurUrolOncol
Great work led by
@MartinMaMDPhD
Andrei Gafita and of course
@CalaisJeremie
. Collaboration with
@RobertReiterMD
@rickysavjani
@JieDengMDPhD
and others
@UCLAJCCC
.
A model that helps predict which patients will benefit the most from PSMA PET scan. Exciting work and collaboration from our
#uclaradonc
Drs.
@MartinMaMDPhD
,
@rickysavjani
,
@JieDengMDPhD
and
@AmarUKishan
Read the full press
1
7
26
1
8
47
@MartinMaMDPhD
crushing it at
@ACRORadOnc
#ACRO22
presenting early results of our SCIMITAR trial. Another situation in which MRgRT allows tighter margins and appears to be associated with lower toxicity
@UCLAJCCC
@viewray
@ASTRO_org
2
2
44
Significant dosimetric benefit to adaptive planning with MRgRT in the post-RP setting out in
@RadiotherapyOn1
. Great work led by John Nikitas and
@laurenmsmiith
using data from the SCIMITAR trial (NCT03541850).
@piet_ost
@alison_tree
@VedangMurthy
@HimanshuNagarMD
@ndesai2005
3
16
44
Thanks to the KureIt Foundation and my team at UCLA including
@CalaisJeremie
@TheBoutrosLab
@UCLAJCCC
. Much to learn about radiorecurrent disease.
@montypal
Proud to share that
#uclaradonc
Dr.
@AmarUKishan
has been awarded a Kure It Rivals Cup Grant for his research project "The Radiographic, Transcriptomic, and Proteomic Foundations of Radiorecurrent Prostate Cancer."
#uclaradoncambition
#uclahealth
2
3
66
7
6
44
Excellent work by stellar PGY-3 Martin Ma and the
@UCLAJCCC
team including
@CalaisJeremie
. Nomograms for clinical aid are forthcoming.
Impact of PSMA/PET in nodal and metastatic upstaging in high risk prostate ca
#ASTRO20
#pcsm
#radonc
📌Nodal upstaging in 19.7%, metastatic in 9.4%
📌Predictors: PSA, PPC, GG, cT, ≥2 HR factors
📌PPC≥50% GG4-5 ➡️occult N1 27.5%
📌PPC≥50% GG5➡️occult M1 20.6%
@MSteinbergMD
3
13
51
1
7
41
Congratulations to
@MartinMaMDPhD
for leading this LEVIATHAN effort. A pooled analysis of local failure after definitive RT. Nice work Martin, and congrats on the Merit Award! Another piece of work from the MARCAP consortium
@DrSpratticus
Local Recurrence Following RT Leads to Second Wave of Distant Metastases!
5
8
57
4
7
40
It was a true honor having the great
@NicholasZaorsky
join us virtually for a lecture to UCLA rad onc residents on SBRT for RCC, highlighting amazing work by himself and others
@ChadTangMD
@_ShankarSiva
@DrAlexLouie
@UCLAJCCC
@AnnRaldow_MD
@MSteinbergMD
0
0
36
Excellent work by outstanding resident Kiri Sandler on the potential effect of WPRT vs. prostate only RT in patients with GS 9-10 disease getting EBRT or EBRT+BT
@UCLAJCCC
@MSteinbergMD
@DrSpratticus
@DrPaulNguyen
4
10
37
Congratulations Martin! Very proud of you. You have hit it out of the park, cleaning house across multiple meetings and a double hat-trick with first authors at
@JCO_ASCO
@EUplatinum
@IJROBP
@RadiotherapyOn1
@EurUrolOncol
@JAMANetworkOpen
. Big win for UW!
Very excited to share that Dr. Martin Ma will be joining UW/FHCC Radiation Oncology after finishing residency in 2023 as an Assistant Professor in our Precision Radiation Oncology program. We look forward to a very bright future together!
@uwradonc
;
@fredhutch
;
@UWMedicine
18
8
145
1
0
38
1
4
36
Assembling a Barbie Dreamhouse while not putting any weight on a surgerized ankle ranks as an all-time personal achievement.
1
1
35
@Sushilberiwal
@MSKCancerCenter
Good chance to plug our ongoing phase II RCT LUNAR (NCT05496959) of 2 cycles Lu177-PSMA + SBRT vs. SBRT alone for oligometastatic disease. Full protocol at
@BJUIjournal
@CalaisJeremie
@CzerninJohannes
@_ShankarSiva
@piet_ost
@MartinMaMDPhD
2
6
35
Great work by stellar
@UCLAJCCC
resident
@Rlevinepstein
. We will certainly be sticking with 40/5 here. Consistent with the MSKCC dose-escalation study as well.
@seanmmcbride
Nice study..is 40Gy/5fx the winner? Dose-Response with Stereotactic Body Radiotherapy for Prostate Cancer: A Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics and Biochemical Control - Radiotherapy and Oncology
2
32
70
4
7
34
Excellent work by
@MartinMaMDPhD
and Tahmineh Romero evaluating differences in BCR, DM, and PCSM between Black and White men receiving definitive RT across 7 NRG trials. (1/n)
3
8
33
@DrSpratticus
@DrAndrewLoblaw
@SbrtSean
@alison_tree
@NicholasZaorsky
@ndesai2005
@DrStish
@seanmmcbride
@HimanshuNagarMD
@alongi_filippo
SCIMITAR initial toxicity results were presented by
@UCLAHealth
resident,
@MartinMaMDPhD
during
#ACRO2022
today. Listen to
@AmarUKishan
summarize the favorable toxicity profile of post-prostatectomy SBRT for prostate cancer.
#MRIdianSMART
#ACRO2022
@HimanshuNagarMD
0
15
39
4
8
32
@ASCO
Our take on advances in salvage radiotherapy -- dose, field size, hormonal therapy, and genomics. Fantastic job by our newest faculty Luca Valle and Trude Wedde.
@DrSpratticus
@UCLAJCCC
@ASTRO_org
@MSteinbergMD
1
10
31
Very insightful article from former
@UCLAJCCC
radonc resident Narek Shavedian
@MSK_RadOnc
and
@reshmajagsi
in
@JAMAOnc
on inaccurate headlines and impact on patients (specifically re: recent breast cancer and RT omission)
0
9
32
We find that re-irradiation in particular has a reasonable safety and efficacy profile for radiorecurrent disease, with SBRT and HDR brachytherapy standing out.
2
1
30
Happy to share work from
@TommyJiang_2023
, an outstanding aspiring urologist and MSIII
@dgsomucla
(who says rad oncs and uros can't get along?)
1
5
30
Great work on the importance of appropriate biopsy technique in radiorecurrent disease. Honored to write the corresponding editorial in
@EUplatinum
with Luca Valle and Lenny Marks
@UCLAJCCC
@abhiAsolanki
@ndesai2005
@VedangMurthy
Delighted to announce our new publication in
@EUplatinum
!
The Role of Multiparametric MRI and MRI–targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the
#FORECAST
Trial
@TaimurShah
@LondonProstate1
@IP_London
1/8
4
25
91
1
8
29
And now there are published phase III data!
NEW—Ultra-hypofractionated radiotherapy is non-inferior to conventionally fractionated radiotherapy for intermediate-to-high risk
#prostatecancer
regarding failure-free survival: 5-year outcomes of HYPO-RT-PC randomised, non-inferiority, phase 3 trial
2
80
89
1
9
27
Two great pieces of work by stellar
@UCLAJCCC
residents Naomi Jiang and Ye Yuan on post-SBRT PSA kinetics and testosterone/QOL patterns:
@MSteinbergMD
@PercyLeeMD
@DrSpratticus
@DrAndrewLoblaw
@SouMyajiT_RO
@DrewMoghanaki
2
7
26
Transcriptomic heterogeneity in Gleason grade group 5 disease -- clues for rational treatment intensification? .
@EUplatinum
@TheBoutrosLab
@JoanneWeidhaas
@DrSpratticus
@BrandonMahal
@RobertReiterMD
@Davicioni
@EricKleinMD
@UCLAJCCC
@MSteinbergMD
2
7
28
Thanks for the highlight
@ASCOPost
. And expert work editing out the background noise of an unhappy toddler!
0
1
26
Thanks very much for the honor and for your continuous support of radiation oncology
@RO_Institute
!
@JAMA_current
And the winner of the 2018 ROI Publication Award is...
@AmarUKishan
for his outstanding research on the comparative effectiveness of treatments for aggressive prostate cancer published in
@JAMA_current
in March. Learn more in the new issue of The Visionary .
1
5
20
0
5
26
Thanks
@UCLAJCCC
for the support! The manuscript in question is out at
@JAMAOnc
w/ co-authors
@MSteinbergMD
@Howie2241
@DrSpratticus
@NRGonc
@EORTC
UCLA researcher and radiation oncologist Dr. Amar Kishan is looking to establish a more personalized treatment plan for men diagnosed with prostate cancers. Through his research, here is what he is discovering:
#UCLAFightsCancer
0
4
17
2
6
27
Great work by
@MartinMaMDPhD
and Mike Xiang, leveraging our multi-institutional high-risk prostate cancer consortium with many colleagues as well as collaborators in nuclear medicine
@CalaisJeremie
Our finding is now online in JAMA Network Open: A nomogram based on PSMA PET/CT was significantly associated with prostate cancer long-term outcomes (DM, PCSM) ➡️Occult, nonlocalized dz may be the main driver of outcomes in high-risk pts.
#AmarUKishan
2
19
73
1
2
25
@DrSpratticus
@alison_tree
@PCaParker
@cpeedell
@SbrtSean
@NicholasZaorsky
@alongi_filippo
@DrAndrewLoblaw
@DrSuneil_PCa
@ZilliThomas
@nickva1
@DarrenLeaning
@piet_ost
@PaulSargos
@KerkmeijerLinda
Our "MIRAGE" RCT is a 1:1 randomization of MRI-guided SBRT vs. CT-guided SBRT. Pre-specified subgroup analysis to include SpaceOAR use.
3
5
25
Superstar
@UCLAJCCC
rad onc resident Neil Parikh nailing it with an oral presentation at ASCO GU
#GU19
.
@MSteinbergMD
@PercyLeeMD
1
3
26
Great trial led by Nick Nickols and
@CalaisJeremie
@UCLAJCCC
2
8
26
A user-friendly tool to predict the risk of identifying occult nodal disease or metastatic disease on PSMA PET/CT in patients with cN0M0 disease by conventional imaging. Kudos to
@rickysavjani
for programming and the whole team for their work
@EurUrolOncol
Drs.
@MartinMaMDPhD
,
@rickysavjani
,
@JieDengMDPhD
, and
@AmarUKishan
's PSMA Risk Calculator is LIVE on our website... !
0
4
17
0
2
24
Kudos to
@UCLAJCCC
resident Luca Valle and an international team including
@GertMeerleer
@declangmurphy
@CalaisJeremie
@NehaVapiwala
for a nice scoping review on the utility of advanced PET imaging prior to SRT
@EurUrolOncol
0
6
24
@dgsomucla
medical student
@TommyJiang_2023
and Luca Valle share our thoughts on contemporary considerations for optimizing salvage RT
@EUplatinum
1
7
24
Great work led by superstar residents Luca Valle
@EricLehrer
Thanks to my many co-authors
@NicholasZaorsky
@DrSpratticus
@rtdess
@RobertReiterMD
@Rlevinepstein
@MSteinbergMD
@BrianJDavisMDPh
@DrPaulNguyen
Jeremie Calais Nick Nickols Jeff Karnes
0
0
23
Interesting study showing toxicity profile of IMRT for pelvic nodal RT in a national cohort.
2
11
23
Yet another abstract award for
@MartinMaMDPhD
! Congrats!
@MartinMaMDPhD
and fellows UCLA co-resident presenting volumetric and dosimetric findings from MIRAGE trial! Should we consider online adaptation for prostate swelling or SV rotation? ITVs for the SV? 🤔👀
#RSS2022
#radonc
@UCLAJCCC
@AmarUKishan
@MSteinbergMD
0
4
25
1
4
22
Truly an honor to be a visiting professor
@UCSFCancer
!
Welcoming
@AmarUKishan
today at
@UCSFCancer
! He shares his inspiring academic journey, challenges, and rewards in setting up the incredible
#MARCAP
consortium! "Rome wasn't built in a day" - but now allows studying novel comparisons in
#prostatecancer
@UCLAJCCC
0
0
16
0
2
23
@PBlanchardMD
@NRGonc
@TheLancet
@felixfengmd
@DrHowardSandler
@jmmrad
@DrewMoghanaki
@SbrtSean
@PCaParker
I believe the p-value threshold for statistical significance for the secondary endpoints was 0.0125, so not significant for MFS.
3
2
22
Thanks for highlighting this work
@StephenRameyMD
, which was led by
@UCLAJCC
resident Naomi Jiang.
Nice paper on PSA response after SBRT for
#ProstateCancer
by
@AmarUKishan
. >1000 pts treated with 35-40 Gy in 5 fractions.
4% biochemical failure overall and only 1% if PSA reached 0.5 or lower. Median nadir PSA 0.2.
#radonc
#ProstateCancerAwarenessMonth
0
15
39
0
2
20
Interested in thoughts!
@SbrtSean
@alison_tree
@DrSpratticus
@HimanshuNagarMD
@seanmmcbride
@TylerSbrt
@ndesai2005
@achoud72
@DrAndrewLoblaw
@nickva1
@DrLesterColl
@DrStish
@viewray
@PCF_Science
11
1
21
Congrats
@ndesai2005
@aleberlin2
NRG-GU010 Protocol Activation! Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
@ndesai200
@UTS
@TheCTSU
2
17
64
1
3
21
@ndesai2005
@PottersMD
Appreciate it Neil. Asking a rhetorical question that attempts to demean the PI is certainly personal. If you don’t want a message to come off as a personal attack, perhaps don’t attack someone personally by suggesting their trial is biased and their ethics are compromised.
1
0
20
@DrSpratticus
@rweichselbaum
@LondonProstate1
@viewray
Interim analysis of will be presented at ASCO GU. Technology-based RCTs are hard to do for a variety of reasons, and I'm happy to note the trial was fully accrued in October 2021.
0
5
18
Thanks! Glad to present the primary endpoint, highlighting the benefit of margin reduction with this technology!
.
@AmarUKishan
presenting MIRAGE testing if aggressive margin reduction via MRgRT will reduce acute Gr ≥2 GU tox
#ASTRO22
✅ Reduced physician scored acute GU tox & acute GI tox
✅ Improved acute IPSS & Epic-26 bowel scores
Congrats to the team incl. my co-res
@MartinMaMDPhD
2
18
67
2
1
19
Tuesday in
@IJROBP
and Thursday in
@EurUrolOncol
-- Well done
@claysmithmd
@UCLAJCCC
! Nice "Tweetorial" as well. Should we escalate therapy for patients with higher Decipher scores? And how?
@DrSpratticus
@HimanshuNagarMD
@Davicioni
@Adam_Weiner535
@RobertReiterMD
@AttardLab
Excited to share our team's recent pub in
@EurUrolOncol
describing the correlation between
#Decipher
score and
#PSMA
upstaging risk among 4625 pts w HR/VHR PCa. Thx to
@AmarUKishan
,
@CalaisJeremie
,
@DrSpratticus
& the whole team.
2
15
50
0
6
20
SBRT to the prostate fossa has been studied in two phase I trials (COH and USC). Here, we expanded this to a phase II design. 100 patients were treated with 30-34 Gy in 5 fractions to the bed (median dose 32 Gy). 69 got CTgRT and 31 were treated with MRgRT
@viewray
1
6
19
@jfcdrr
@EvanThomas84
@the_RSS
@marslain
SBRT is an acceptable option for HR and VHR per NCCN. For high risk, it says “nodal radiation should be considered” but does not comment on fractionation.
@DrAndrewLoblaw
@VedangMurthy
@DrDarrenPoon
Good published data for 25/5
2
6
20
Luca Valle thoughts on SBRT/SABR for oligometastatic prostate cancer
@ASCO
@UCLAJCCC
@piet_ost
@_ShankarSiva
@neerajaiims
@DrYukselUrun
@Mat_Guc
1
3
19
@TylerSbrt
@tommyrochmn
@alison_tree
@piet_ost
@PottersMD
100%, Tyler. As a professional, why wouldn’t my time be worth compensation? If I am asked to serve on an advisory board after hours, or give a presentation, that means taking my time away from something else, including my family.
2
2
19
Long duration ADT is highly underutilized w/ RT, with racial disparity. Need to do better. Also a warning for efficacy studies that don't have ADT duration information...
@EurUrolOncol
@AnnRaldow_MD
@DrPaulNguyen
@DrSpratticus
@jamesbyu
@MSteinbergMD
0
6
19
@seanmmcbride
QOD. we found less toxicity with this approach (as did Chris King in his original trial).
@DrAndrewLoblaw
PATRIOT trial did find less acute (but not late) toxicity with qweekly, with possibly more salvage ADT in the qweekly group
2
2
18
@weeloonong
leading this latest MARCAP effort. As
@SouMyajiT_RO
mentioned, just a preview of the full analysis to come
@DrSpratticus
0
8
18
@PCFnews
Congratulations to all my fellow awardees, and thank you
@PCF_Science
and
@ASTRO_org
for the support. Thankful to have a great mentorship team
@UCLAJCCC
with
@JoanneWeidhaas
@TheBoutrosLab
and Matt Rettig!
2
2
18
Thanks for the invitation and thanks to
@TROGfightcancer
for joining MARCAP. Will need to visit for real one of these days!
A great presentation to wrap up the TROG 2022 Genitourinary Tumour Group Session, with our international speaker A/Prof Amar Kishan discussing ADT and RT for Prostate Cancer - implications from the MARCAP Consortium
@AmarUKishan
#TROG2022
0
1
9
2
2
18
Ask questions about the MIRAGE trial using the
#MIRAGEQA
tag and I will try to respond in real-time! There have been a number of questions sent in over the past 72 hours so I will tackle those first.
6
4
18
Local Failure and Survival After Definitive Radiotherapy for Aggressive
#ProstateCancer
: An Individual Patient-level Meta-analysis of Six Randomized Trials
@AmarUKishan
@DrSpratticus
@RobertReiterMD
3
24
47
2
0
18
@Sushilberiwal
@ARRO_org
@ACROresident
@DrSpratticus
@RTendulkarMD
@DrAndrewLoblaw
Definitely practice-changing (or affirming). Worth noting it was selected high-risk (2 of T3-4, GS 8-10, and PSA 40 or more).
2
1
18
@TylerSbrt
@UCSDRadMed
@seanmmcbride
@sophia_kamran
@SbrtSean
@DrRanaMcKay
@DrTylerStewart
@AdityaBagrodia
@HimanshuNagarMD
@mharisinghani
And a corollary publication from the Green J about toxicity just in press as well.
@KerkmeijerLinda
1
7
16
Thanks for highlighting our trial. And yes, the background might as well be a mirage as my home office doubles as a kids’ playroom.
Emerging Insights on
#MRI
Guided
#Radiotherapy
for
#ProstateCancer
@ACRRFS
@ACRYPS
@RadiologyACR
@ARRS_Radiology
@RSNA
@RadiologyUcla
@AmarUKishan
@RadiologyUSC
@UTSW_Radiology
@OHSURadiology
@viewray
@MayoRadiologyAZ
@UofURadiology
0
2
4
0
2
17
@alison_tree
@nickva1
@EmmaHall71
@DrSuneil_PCa
@DrAndrewLoblaw
@cpeedell
@royalmarsdenNHS
@ICR_CTSU
@Accuray
Kudos to you,
@nickva1
.
@EmmaHall71
and the whole team. Extremely impressive BCR rated and very low five year toxicity in an RCT of SBRT for prostate. Incredible achievement and can’t wait for
@nickva1
plenary on Monday!
0
2
16
@TylerSbrt
@UCSDRadMed
@seanmmcbride
@sophia_kamran
@SbrtSean
@DrRanaMcKay
@DrTylerStewart
@AdityaBagrodia
@HimanshuNagarMD
@mharisinghani
Awesome trial for sure. Worth noting, it was regional disease (the "r" in the endpoint rDMFS) that was reduced, not distant mets. Impressively, many of the patients who had imaging at BCR did have advanced imaging.
2
3
17
@a_dalpra
@dr_jonathant
@IdaSonni
@saratchanderRO
@ZilliThomas
@abhiAsolanki
Current volumes likely cover too much bladder superiorly/anteriorly, and not enough of the rectoprostatic angle/VUA inferiorly. It will be very important to evaluate post-SRT patterns of failure as well, which is an ongoing area of work led by
@JeremieCalais
2
2
15
@alison_tree
@HimanshuNagarMD
@TylerSbrt
@seanmmcbride
@sophia_kamran
@DrSpratticus
@SbrtSean
@RonaldChenMD
@whallradonc
Our direct RCTat
@UCLAJCCC
, MIRAGE, is nearly 50% accrued with a protocol-specified interim analysis planned within the year.
1
3
15
Second in a three article series led by Luca Valle — our take on managing high risk prostate cancer
.
@AmarUKishan
,
@DrSpratticus
& their co-authors discuss treatment-intensification strategies in patients with high-risk
#prostatecancer
receiving radiotherapy:
#ASCODailyNews
#pcsm
0
10
15
1
5
15
Incredibly important study. Congratulations
@VedangMurthy
@docpriyamvada
Very pleased to share the results of the eternal question on the usefulness of Pelvic RT in High Risk Prostate cancer. Hope the debate will settle now. Thanks for the great support.
@TataMemorial
@ACTREC_TMC
@docpriyamvada
#JCO
@ASCO_pubs
@APCCC_Lugano
32
111
326
0
0
15
@SameerKeoleMD
@ParikhSimul
Adaptive replanning may be part of it, but would note that in our RCT, we saw better toxicity with 0 adapted fractions. Instead, I contend the major advantage is the vastly improved IGRT that facilitates aggressive margin reduction.
6
0
15
The bottom line: Patients treated with MRgRT-based SBRT had significantly lower acute grade ≥2 GU toxicity (24.4%, vs. 43.4%) and lower acute grade ≥2 GI toxicity (0% vs. 10.5%). (2/n)
1
5
16
@AllenMoMDPhD
@UCLAHealth
@MonteRadOnc
Great group. Thanks Allen. Let's also disclose that you asked me to present on MRgRT, before this weekend. I guess I'm welcome in some New York institutions!:)
3
0
15